Health care
DiscloseDisclosure agenda
See how concentrated each market is, how that has changed, and who the largest firms are. Every figure keeps its market definition and source; concentration alone does not establish harm or unlawful conduct.
Structure × evidence atlas
Horizontal position is latest published HHI. Vertical rows are categorical evidence states; missing HHI stays in its own lane.
Focused profile
Focused profile
Digital platforms · 2026
Estimated public screen
Public inputs support a descriptive estimate, with uncertainty retained.
Comparison set
0/4Add two profiles to open a full comparison.
Select 2 moreOpen data packet
Pull the atlas into notebooks, spreadsheets, source review, or the public data console.
Why this atlas exists
12
markets
8
sectors
8
threshold review
4
data gaps
Sector intelligence
Digital platform systems
Search referrals, browser page views, mobile operating systems, social referrals, and AI assistant usage retain separate denominators, source histories, and interpretation limits.
Explore where public evidence shows concentrated power, where the record is strong enough for scrutiny, and where missing data should become a government disclosure agenda.
12
Profiles
8
Review threshold
4
Evidence gaps
1 markets in view, 1 in the all signals layer. HHI, source coverage, and the government lane re-rank together.
Latest source access
Jul 21, 2026
Public evidence ledger
Freshest vintage
2026
0 HHI-ranked in this view
Agency-ready
2
Verified with high confidence
Evidence packets
17
22 related briefings
The matrix reads the current filters by sector, action posture, public-data gaps, and agency-ready evidence.
Highest-pressure sector
Health care: Disclosure agenda
1 filtered profile, 1 disclosure gap, 0 agency-ready.
Disclosure agenda
Profile in focus
U.S. pharmacy benefit managementPharmacy benefit management services profile based on FTC public findings. The FTC reports top-three and top-six aggregate shares but not enough individual PBM market shares in the public press-release record to compute HHI.
Market signal
HHI
Withheld
CR4
N/A
Top firm
N/A
Public evidence packet
Reusable route bundle
Government next step
Compel reusable market-share evidence
Treat missing HHI, CR4, or participant share data as a governance problem, not a neutral absence.
Filtered public-interest docket
The atlas now translates the same filters into action priorities: investigate concentrated power, disclose missing evidence, monitor rising concentration, or keep a public baseline current.
0
1
0
0
What public filing, subpoena, or reporting rule would make concentration measurable here?
1 filtered · 0 HHI ranked · 0 threshold review · 1 data gaps
| Rank | Market | Sector | HHI | CR4 | Top firm | Class | Data status | Source basis | Open |
|---|---|---|---|---|---|---|---|---|---|
| 1 | U.S. pharmacy benefit management United States · 2023 | Health care | Withheld | N/A | N/A | Not calculated | Incomplete data | Federal Trade Commission 1 source · High confidence | Open profile |
Market share treemap
A treemap reads concentration at a glance: one dominant tile signals a market held by a single firm, while many even tiles signal real rivalry. Switch markets to compare.
Transportation · United States
HHI
Withheld
Not firm-level
Top firm
17.8%
Largest share
CR4
69.0%
Top 4 firms